)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sino Biopharmaceutical (1177) investor relations material
Sino Biopharmaceutical H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary18 Aug, 2025
Executive summary
Revenue for the six months ended 30 June 2025 rose 10.7% year-over-year to RMB17.57 billion, driven by strong growth in innovative products and increased dividend income.
Profit attributable to owners from continuing operations surged 140.2% year-over-year to RMB3.39 billion; underlying profit (adjusted/non-HKFRS) up 101.1% to RMB3.09 billion.
Innovative products revenue grew 27.2% year-over-year, accounting for 44.4% of total revenue, with oncology medicines contributing 38.1%.
The Group completed the disposal of its osteoporosis and marine pharmaceuticals business in March 2024 to focus on four core therapeutic areas: oncology, liver/metabolic, respiratory/infectious diseases, and surgery/analgesia.
Interim dividend of HK5 cents per share was declared for the period.
Financial highlights
Gross profit margin improved to 82.5% in 2025 H1 from 82.1% in 2024 H1.
Selling and administrative expenses to revenue ratio remained stable at 42.9%.
R&D costs were RMB3.19 billion, representing 18.1% of revenue.
Cash and bank balances (current assets) at period end were RMB11.1 billion; total fund reserves (including bank deposits and wealth management products) reached RMB30.5 billion.
Basic EPS from continuing operations increased 145.7% year-over-year to RMB18.82 cents.
Outlook and guidance
Nearly 20 innovative products are expected to be approved for marketing between 2025 and 2027, with over half projected as blockbusters (peak sales >RMB2 billion).
By 2027, innovative products are projected to account for 60% of total sales.
Internationalization and out-licensing anticipated to become new recurring revenue streams, accelerating performance growth.
Major data readouts expected in 2025–2026 for key pipeline assets in oncology, respiratory, and other areas.
Strategic acquisitions, such as LaNova Medicines, to strengthen innovation and R&D capabilities.
Assess LaNova Medicines' oncology assets.
Explain TQB3616's enhanced CDK inhibition.
How will Sino Biopharm achieve carbon neutrality?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sino Biopharmaceutical earnings date
H2 202519 Mar, 2026
Next Sino Biopharmaceutical earnings date
H2 202519 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sino Biopharmaceutical Limited is a Chinese pharmaceutical company focused on the research, development, manufacturing, and distribution of a wide range of pharmaceutical products. The company’s portfolio covers therapeutic areas such as oncology, hepatitis, cardiovascular, orthopedics, and respiratory diseases. Sino Biopharmaceutical emphasizes innovation through its research and development efforts, producing both innovative and generic drugs to meet healthcare needs in China and internationally. The company is headquartered in Beijing, China, and its shares are listed on the Hong Kong Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage